mbiomics GmbH, a German microbiome biotech company developing the first generation of effective microbiome-based therapeutics has closed €13 million ($ 15 million) of a series A financing round led by MIG Capital.
High-Tech Gründerfonds and Bayern Kapital joined the funding round together with a pool of private seed investors.
mbiomics uses its proprietary, tailored high-resolution profiling platform and computational techniques to generate precision data on microbiota modulation. The technology provides an improved understanding of the complex interactions between the gut microbiome and the host, allowing mbiomics to design more effective microbial consortia that can be delivered to patients as precision therapies.